TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

Congratulations to Dennis Slamon, M.D., Ph.D., Professor of Medicine, and Chief of the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine (DGSOM) (pictured above) co-founder of TORL BioTherapeutics LLC on a successful launch!

                                                                                                      READ ARTICLE HERE